other
confidence high
sentiment neutral
materiality 0.25
Xeris files Strongbridge unaudited 9M 2021 financials: net loss $31.6M, rev $29.9M
Xeris Biopharma Holdings, Inc.
- Strongbridge nine months ended Sep 30, 2021: net loss $31.6M vs $33.1M prior-year.
- Revenue $29.9M vs $22.5M prior-year, primarily from Keveyis sales.
- Cash and equivalents $55.3M; accumulated deficit $337.2M as of Sep 30, 2021.
- Acquisition by Xeris closed Oct 5, 2021; filing satisfies SEC requirement for acquired company financial statements.